WALTHAM, Mass.--(BUSINESS WIRE)--Entasis Therapeutics, a company focused on the discovery and development of breakthrough anti-infective products, announced today the appointment of Greg Norden to the company’s Board of Directors.
“Greg is an outstanding leader in our industry, and I am delighted to welcome him to our Board,” said Manos Perros, Chief Executive Officer of Entasis. “Greg joins our team during an exciting time for the company, with our second flagship program, ETX2514, entering the clinic. Greg brings a wealth of industry knowledge and expertise which will be an invaluable asset to Entasis as we advance our programs.”
